COMP <GO>
HCM vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
HUTCHMED (China) Limited (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: HCM 2
— MRK 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MRK
LAST: $13.15 (-3.24%) • MKT CAP: $2.37B
roic
-2.50%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HCM VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HCM | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -2.50% | 20.70% | -23.20 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.32% | 3.42% | -6.74 | MRK | /fcf-yield <GO> |
| Operating Margin | -7.10% | 34.30% | -41.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 28.10% | +39.90 | HCM | /net-margins <GO> |
| Revenue Growth (YoY) | -13.00% | 1.30% | -14.30 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.63 | 5.19 | -1.56 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.0 | 51.7 | -4.70 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 4.8x | 18.4x | -13.60 | HCM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.37B | $361.02B | -$358.65B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HCM REV | MRK REV | HCM GROSS % | MRK GROSS % | HCM FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $548.5M | $65.01B | 38.7% | 74.8% | -$78.8M | $12.36B |
| FY 2024 | $630.2M | $64.17B | 44.6% | 76.3% | -$17.4M | $18.10B |
| FY 2023 | $838.0M | $60.12B | — | — | $219.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HCM // BETA —
MRK // BETA 0.92